Elliot Ehrich

Elliot Ehrich is the Chief Medical Officer (CMO) and Executive Vice President (EVP) of Translational Science. He has dedicated his career to translating scientific discoveries into new medicines for illnesses that lack effective treatments or are inadequately addressed by existing therapies. With over 25 years of experience in the pharmaceutical and biotechnology industries, Ehrich has led or directly contributed to the discovery, development, and successful registration of eight medicines across a spectrum of therapeutic areas.

Ehrich joined LifeMine from Skyhawk Therapeutics, where he served as President and led research, drug discovery, and drug development activities. Prior to that, he was a Venture Partner at 5AM Ventures, a venture capital firm focused on early-stage life science companies. He spent 18 years at Alkermes, Inc., where he served as Executive Vice President of Research & Development and Chief Medical Officer. At Alkermes, he initiated a transformation of the company’s R&D focus from medicines based on drug delivery technology to a diverse portfolio of novel, proprietary small molecule therapeutics. He led the discovery, development, and FDA registration of a series of medicines for multiple therapeutic indications, including schizophrenia, alcohol and opioid dependence, and multiple sclerosis. He also initiated a novel cytokine program for the treatment of malignancy, which is currently in phase 3 clinical development.

Ehrich began his industry career in the clinical pharmacology group at Merck Research Labs, where he gained extensive experience in the assessment of human pharmacokinetics and drug-exposure-response relationships. He also worked in pulmonary-immunology clinical development at Merck. Ehrich holds a B.A. in Biochemistry from Princeton University and was a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. He received an M.D. from Columbia University, completed an internship and residency in internal medicine at Stanford University, and completed a clinical fellowship in immunology and rheumatology at Stanford University. Additionally, he completed a Cancer Research Institute-sponsored postdoctoral fellowship in T cell biology in the laboratory of Professor Mark Davis at Stanford University.